JP2022525425A5 - - Google Patents
Info
- Publication number
- JP2022525425A5 JP2022525425A5 JP2021556402A JP2021556402A JP2022525425A5 JP 2022525425 A5 JP2022525425 A5 JP 2022525425A5 JP 2021556402 A JP2021556402 A JP 2021556402A JP 2021556402 A JP2021556402 A JP 2021556402A JP 2022525425 A5 JP2022525425 A5 JP 2022525425A5
- Authority
- JP
- Japan
- Prior art keywords
- abiraterone
- crystalline
- excipient
- pharmaceutical preparation
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820076P | 2019-03-18 | 2019-03-18 | |
| US62/820,076 | 2019-03-18 | ||
| US201962942111P | 2019-11-30 | 2019-11-30 | |
| US62/942,111 | 2019-11-30 | ||
| PCT/US2020/023066 WO2020190900A1 (en) | 2019-03-18 | 2020-03-17 | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525425A JP2022525425A (ja) | 2022-05-13 |
| JP2022525425A5 true JP2022525425A5 (https=) | 2023-03-27 |
Family
ID=72521270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556402A Pending JP2022525425A (ja) | 2019-03-18 | 2020-03-17 | アビラテロン－環状オリゴマー薬学的製剤ならびにその形成方法および投与方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220362264A1 (https=) |
| EP (1) | EP3941478A4 (https=) |
| JP (1) | JP2022525425A (https=) |
| CN (1) | CN113825514A (https=) |
| AU (1) | AU2020240017A1 (https=) |
| BR (1) | BR112021018540A2 (https=) |
| CA (1) | CA3133620A1 (https=) |
| IL (1) | IL286416A (https=) |
| WO (1) | WO2020190900A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10792292B2 (en) | 2019-03-06 | 2020-10-06 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| US11957696B2 (en) | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101738369B1 (ko) * | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | 핫 멜트 압출된 제어 방출 투여형 |
| WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
| US20140287039A1 (en) * | 2013-03-15 | 2014-09-25 | Iceutica Inc. | Abiraterone Acetate Formulation |
| EP3247334A1 (en) * | 2015-01-20 | 2017-11-29 | Merck Patent GmbH | Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer |
| WO2017037647A1 (en) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Stable pharmaceutical compositions of abiraterone |
| TWI717629B (zh) * | 2017-08-28 | 2021-02-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Cyp17抑制劑的藥物組合物及其製備方法 |
| WO2019060525A1 (en) * | 2017-09-22 | 2019-03-28 | Dispersol Technologies, Llc | PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF |
-
2020
- 2020-03-17 AU AU2020240017A patent/AU2020240017A1/en not_active Abandoned
- 2020-03-17 WO PCT/US2020/023066 patent/WO2020190900A1/en not_active Ceased
- 2020-03-17 BR BR112021018540A patent/BR112021018540A2/pt not_active IP Right Cessation
- 2020-03-17 JP JP2021556402A patent/JP2022525425A/ja active Pending
- 2020-03-17 CA CA3133620A patent/CA3133620A1/en active Pending
- 2020-03-17 US US17/437,144 patent/US20220362264A1/en not_active Abandoned
- 2020-03-17 EP EP20772679.5A patent/EP3941478A4/en not_active Withdrawn
- 2020-03-17 CN CN202080036072.5A patent/CN113825514A/zh active Pending
-
2021
- 2021-09-14 IL IL286416A patent/IL286416A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534320A5 (https=) | ||
| JP2022546471A5 (https=) | ||
| AU2002222567B2 (en) | Composition improved in solubility or oral absorbability | |
| JP6522853B2 (ja) | Ｓｏｍｃｌ−９１１２固体分散体、その製造方法およびそれを含むｓｏｍｃｌ−９１１２固体製剤 | |
| JP2023182674A (ja) | アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法 | |
| HUT62461A (en) | Process for producing pearl compositions coated with active ingredient of low solubility | |
| TW200304379A (en) | Pharmaceutical composition | |
| KR101872561B1 (ko) | 아로마타제 억제제를 포함하는 제약 조성물 | |
| BRPI0922804B1 (pt) | composição farmacêutica em uma forma de dosagem sólida compreendendo bendamustina e um excipiente farmaceuticamente aceitável | |
| CN107278152A (zh) | 醋酸阿比特龙复合物、其制备方法及包含它们的药物组合物 | |
| JP2007517879A (ja) | Ｃｃｉ−７７９経口投与用の直接圧縮可能な医薬組成物 | |
| WO2023179774A1 (en) | Amorphous solid dispersions and pharmaceutical compositions comprising the same | |
| JP2022525425A5 (https=) | ||
| WO2016126058A2 (ko) | 두타스테라이드 함유 고체 분산체 및 이를 포함하는 조성물 | |
| CN108012526A (zh) | 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法 | |
| CN101898962B (zh) | 大黄酸晶b型固体物质及制备方法与用途 | |
| EA023294B1 (ru) | Фармацевтическая композиция, содержащая солифенацин | |
| CN107921004A (zh) | 包含3‑(5‑氨基‑2‑甲基‑4‑氧代基‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮的药物组合物 | |
| CN102933213A (zh) | 放射增敏剂组合物 | |
| CN115702897A (zh) | 一种包含沃替西汀前药或其盐的药物组合物 | |
| US20110262540A1 (en) | Solid Pharmaceutical Composition Comprising Exemestane | |
| CN107496422A (zh) | 苦参碱二聚体a和b在制备抗炎或抗肿瘤药物制剂中的应用 | |
| CN113350349A (zh) | 奥拉帕尼溶出增强组合物 | |
| CN111683659B (zh) | 一种氨基吡喃衍生物的组合物 | |
| CN101906100B (zh) | 罗通定晶c型固体物质与制备方法与用途 |